|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 中国消除麻疹的关键技术问题:专家解读共识显示文摘中国卫生部发布《2006—2012年全国消除麻疹行动计划》以来,全国采取了一系列消除麻疹策略与措施并取得明显进展,但中国处于消除麻疹的关键时期,面临着新的挑战,麻疹流行病学特征也发生了变化,尤其需要统一和澄清对一些技术问题的认识。中国疾病预防控制中心(Center for Disease Control and Prevention,CDC)免疫规划中心收集、汇总各级CDC专业人员近年来关注的问题,并会同世界卫生组织驻华代表处,组织国内外专家深人研讨了主要的技术问题,包括消除麻疹与接种疫苗、麻疹病例的传染来源、保护〈8月龄婴儿、爆发疫情的应急免疫活动、医院传播的作用和控制意义、特殊人群及场所等,形成专家解读共识,供相关部门和专业人员在消除麻疹中参考。 | 苏琪茹 徐爱强 Peter Strebel 许文波 郝利新 周勇 李慧 庞星火 马超 张燕 方刚 崔富强 丁峥嵘 沈永刚 安志杰 张永基 谢淑云 William Schluter 余文周 郑景山 夏伟 王青 郑慧贞 张延炀 张丽杰 段梦娟 杨维中 Lance Rodewald 李黎 罗会明 | 2014 | 中国疫苗和免疫2014，20，3： | 137 |
| 2 | 新型冠状病毒肺炎疫情紧急研究议程:传播和非药物缓疫策略显示文摘2019年12月29日,武汉市某医院报告了一起不明原因重症肺炎聚集性病例事件,中国政府核实后通报了世界卫生组织(WHO)[1]。2020年1月8日,此次暴发的病原被确认为新型冠状病毒,即2019新型冠状病毒(2019-nCoV),其基因序列被迅速提交WHO。1月30日,WHO宣布将新型冠状病毒感染的肺炎疫情列为'国际关注的突发公共卫生事件'[2]。病原确认后的1个月中,科学家们通过研究已经阐述了诸多重要问题,给疫情的理解、预测和防控带来很多帮助[1,3,4,5,6,7]。尽管我们对2019-nCoV的认识已逐步深入,但很多问题仍然缺乏答案或不够精确,亟待解决。 | 中国疾病预防控制中心新型冠状病毒肺炎疫情防控技术组 冯子健 陈秋兰 冯录召 李中杰 黎舒 秦颖 王晴 杨孝坤 殷文武 张慕丽 张婷 安志杰 李媛秋 吴丹 尹遵栋 俞海亮 陈伟 夏愔愔 张若尘 Lance Rodewald | 2020 | 中华流行病学杂志2020，41，2： | 35 |
| 3 | 新型冠状病毒疫苗研发进展和思考显示文摘2019年底中国武汉发生2019冠状病毒病(Coronavirus disease 2019,COVID-19)暴发疫情。2020年1月30日WHO宣布将该疫情列为国际关注的突发公共卫生事件,3月12日宣布为大流行。截至2020年4月3日,全球报告972303例COVID-19确诊病例,死亡50321例;其中中国报告82802例,死亡3331例。为应对COVID-19疫情进一步传播,多国已宣布启动COVID-19疫苗研发工作。本文综述了全球COVID-19疫苗研发的初步进展,并对疫苗研发和使用提出相关建议。 | 孙校金 王富珍 安志杰 Lance Rodewald 尹遵栋 | 2020 | 中国疫苗和免疫2020，26，3： | 13 |
| 4 | 中国推进消灭脊髓灰质炎终结战略计划技术问题:世界卫生组织专家解读显示文摘中国积极推进消灭脊髓灰质炎(脊灰)终结战略计划,分阶段将灭活脊灰病毒疫苗(Inactivated Poliovirus Vaccine,IPV)纳入免疫规划,预期2016年4月与全球同步停服三价(Trivalent)口服脊灰减毒活疫苗(Oral Poliomyelitis Attenuated Live Vaccine,t OPV),开始接种二价(Bivalent)OPV(b OPV)。为澄清对一些技术问题的认识,世界卫生组织驻中国代表处会同国内外相关专家,讨论了中国部分专业人员提出的主要技术和政策问题,包括停用OPV的原因,b OPV替代t OPV使用的步骤,转换前减少风险的准备等,形成专家解读,供相关部门和专业人员在推进消灭脊灰终结战略计划中参考。 | 左树岩 Lance Rodewald Roland Sutter Jackie Fournier-Caruana William Schluter Sergey Diorditsa | 2015 | 中国疫苗和免疫2015，21，4： | 9 |
| 5 | Effectiveness of Catch-Up Vaccinations after COVID-19 Containment--China,2020显示文摘Introduction:In the early stages of the coronavirus disease 2019(COVID-19)epidemic in China,the highest level of public health emergency response(Level 1 Response)was launched in all province-level administrative divisions(PLADs)across the country.Provision of vaccination services was selectively suspended due to the physical distancing and gathering restrictions required of Level 1 Response.The purpose of this paper is to evaluate the impact of COVID-19 on vaccination services and the effectiveness of selective vaccination service suspension and catch-up vaccinations in China.Methods:Vaccine doses administered,routine vaccination coverage levels,catch-up vaccine doses administered,and coverage levels after the catch-up campaign were determined from individual vaccination records in sampled clinics,standard routine immunization administrative coverage reports,and catch-up vaccination activity reports submitted by PLADs between October 2019 and October 2020.Results:National Immunization Program(NIP)and non-NIP vaccine doses administered in sampled clinics decreased by 80% and 90%,respectively,compared with doses administered before the COVID-19 pandemic.Coverage with the birth dose of hepatitis B vaccine(HepB1)and the Bacillus Calmette-Guérin vaccine(BCG)—two vaccinations recommended to continue throughout the epidemic due to their timecritical nature—were maintained at over 85%,while coverage of other NIP vaccines decreased to below 60%by February 2020.Catch-up vaccination coverage of the 29 PLADs,excluding Xinjiang and Xizang(Tibet),began in April 2020 and exceeded 90%;Hubei catch-up coverage was 95% by October 2020.Conclusions and Implications for Public Health Practice:The COVID-19 pandemic had a great impact on China’s vaccination services.During the epidemic and time of local transmission of the coronavirus,HepB1,BCG,rabies vaccine for postexposure prophylaxis,and tetanus antitoxin(TAT)for wound prophylaxis were maintained at high levels.Of the 69 million vaccine doses postponed during the time of local transmission of the coronavirus,94% were administered in the catch-up campaign.China’s pandemic immunization practices may provide evidence for other countries’immunization programs. | Jing Wu Wenzhou Yu Lei Cao Lingsheng Cao Lance Rodewald Jiakai Ye Yifan Song Li Li Xiaoxue Liu Ning Wen Fuzhen Wang Lixin Hao Yixing Li Hui Zheng Keli Li Chao Ma Dan Wu Yanmin Liu Guomin Zhang Zhijie An Huaqing Wang Zundong Yin | 2020 | China CDC weekly2020，2，50： | 6 |
| 6 | Compliance among infants exposed to hepatitis B virus in a post-vaccination serological testing program in four provinces in China显示文摘Background:Mother to child transmission of hepatitis B virus(HBV)remains the most common form of HBV infection in China.Prevention of HBV vertical transmission involves timely administration of the complete hepatitis B vaccine(HepB)series and hepatitis B immunoglobulin.Post-vaccination serological testing(PVST)is utilized to determine an infant's outcome after HBV exposure and completion of HepB series.We aim to determine the frequency of compliance with a PVST testing cascade for HBV infected mothers and analyze factors associated with infant lost to follow up(LTFU).Methods:We conducted a retrospeaive cohort review of previously collected data in Fujian,Jiangxi,Zhejiang and Chongqing provinces in China from 1 June 2016-31 December 2017.The study population included all HBV-exposed infants and their mothers.SAS software was used for statistical analyses.Bivariate and multivariate regression analyses(presented in odds ratio[OR]with 95%confidence intervals[CI])were used to compare the proportional differences of factors associated with PVST not being completed.Results:Among enrolled 8474 target infants,40%of them transferred out of the study provinces without further information and 4988 were eligible for PVST.We found 20%(994)of infants were not compliant with the testing cascade:55%of LTFU occurred because parents refused venous blood sample collection or failure of sample collection in the field,16%transferred out after 6 months of age,and 10%of families chose to have independent,confidential PVST completed without reporting results.High PVST noncompliance rates were more likely to be from Fujian(aOR=17.0,95%CI:9.7-29.9),Zhejiang(aOR=5.7,95%Cl:3.2-10.1)and Jiangxi(aOR=1.9,95%CI:1.0-3.4),and from HBV e antigen positive mother(aOR=1.2,95%CI:1.1-1.4).Conclusions:This study found that the LTFU rate reached 20%in PVST program,which was a significant problem.We recommend implementing a national elearonic information system for tracking HBV at risk mother-infant pairs;encourage further research in developing a less invasive means of completing PVST,and take effective measures nationally to reduce HBV stigma.Without reducing the loss to follow up rate among infants eligible for PVST,elimination of vertical HBV transmission will be impossible. | Hui Zheng Guo-Min Zhang Po-Lin Chan Fu-Zhen Wang Lance Everett Rodewald Ning Miao Xiao-Jin Sun Zun-Dong Yin Jeffrey Edwards Hua-Qing Wang | 2019 | Infectious Diseases of Poverty2019，8，4： | 5 |
| 7 | The National Immunization Advisory Committee in China:Roles of National Experts in Making Evidence-Based Recommendations for Immunization显示文摘In 2017,the State Council requested the National Health and Family Planning Commission(NHFPC),known as the Ministry of Health(MoH)before 2013 and as the National Health Commission(NHC)after 2018,to establish China’s National Immunization Advisory Committee(NIAC)(1).The NIAC acts as China’s National Immunization Technical Advisory Group(NITAG)—a deliberative body of national experts who advise national authorities and policy makers with evidence-based recommendations on immunization policy and program(2-3). | Chao Ma Lance Rodewald Zhijie An Zundong Yin Zijian Feng | 2019 | China CDC weekly2019，1，2： | 5 |
| 8 | Guangdong’s Study of the Effectiveness of China’s Inactivated Vaccines Against the SARS-CoV-2 B.1.617.2(Delta)Variant显示文摘Guangdong CDC published in preprint a critically important study of the effectiveness of China’s inactivated vaccines against the B.1.617.2(Delta)variant of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)—a strain of the virus that causes coronavirus disease 2019(COVID-19)and is circulating globally(1–2).The Delta variant managed to get through China’s strong international border quarantine protection and spark an outbreak in Guangdong Province in May–June 2021.While the outbreak was being stopped using guidance of the Protocol for Prevention and Control of COVID-19(3),the investigators took advantage of provisions in the Protocol that identified close contacts of anyone infected with SARS-CoV-2。 | Fuzhen Wang Zhijie An Lance Rodewald Dan Wu Lin Tang Hui Zheng Qianqian Liu George F.Gao Zundong Yin | 2021 | China CDC weekly2021，3，34： | 3 |
| 9 | Progress Toward Measles Elimination--China,January 2013-June 2019显示文摘What is already known about this topic?China has historically had high measles incidence and many associated deaths.A comprehensive measles elimination plan during 2006-2012 substantially reduced measles incidence;however,a resurgence occurred during 2013-2015.What is added by this report?In China,measles surveillance,outbreak response,research,and program evaluation were used to strengthen routine immunization and target immunization activities for eliminating measles.Measles incidence declined from 31 per million in 2015 to 2.8 in 2018;only one measles-associated death has been reported during 2018-June 2019.What are the implications for public health practice?The World Health Organization-recommended strategy to eliminate measles can be effective,including in large,densely populated countries like China. | Chao Ma Lance Rodewald Lixin Hao Qiru Su Yan Zhang Ning Wen Chunxiang Fan Hong Yang Huiming Luo Huaqing Wang James LGoodson Zundong Yin Zijian Feng | 2019 | China CDC weekly2019，1，2： | 3 |
| 10 | Vaccinate with Confidence and Finish Strong显示文摘China’s sustained containment of the coronavirus disease 2019(COVID-19)epidemic has spared over 99%of the mainland of China’s 1.4 billion people from exposure to and infection with severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)and its variants for an astonishing two and a half years.Although the whole-of-government,whole-of-society containment effort has its own socioeconomic costs,the now-called dynamic COVID-zero strategy purchased a rare commodity—tranquil time with relatively little suffering and death from COVID-19 to develop and deploy tools for escaping the pandemic:diagnostics,vaccines,antivirals,and knowledge(1). | Lance Rodewald Dan Wu Zundong Yin Zijian Feng | 2022 | China CDC weekly2022，4，37： | 2 |
| 11 | 以疫苗接种提高人群免疫力来巩固中国成功遏制新型冠状病毒肺炎疫情的策略与挑战显示文摘冯子健及其同事认为在中国持续消除新型冠状病毒肺炎(COVID‑19)本土病例,为新冠病毒疫苗接种政策提供了灵活性,并讨论了预期的挑战,以及开展系统性监测的必要性,以使疫情应对措施中预防接种的部分保持在正确的轨道上。新型冠状病毒(以下简称新冠病毒)在中国的流行不同寻常,但也并非独一无二。通过实施全民参与的强有力的非药物干预措施,新冠病毒在2020年4月得到了有效遏制1。从疫情暴发开始就采取的总体政策是(现在依然是)“本土传播零容忍”。成功地维持18个月只发生2例新冠病毒肺炎死亡病例(图1)。零容忍政策具有的重大意义在于持续消除新冠病毒本土流行和中国新冠病毒疫苗接种策略。 | 安志杰 王富珍 潘安 尹遵栋 Lance Rodewald 冯子健 胡莹雪 张琳(译) | 2022 | 英国医学杂志中文版2022，25，4： | 1 |
| 12 | 美国免疫规划的决策体系及其演变显示文摘为借鉴美国免疫规划决策的经验,现对美国国家疫苗咨询委员会和免疫实施咨询委员会的建立、免疫程序的协调统一、疫苗损害的补偿、疫苗筹资与预防接种相关法律法规、统一的经济学分析方法、制定建议的循证方法的演变过程及影响因素进行综述。 | 孙宁宁 李黎 Lance Everett Rodewald | 2014 | 中国疫苗和免疫2014，20，2： | 1 |
| 13 | Vaccination Guidelines During and After the COVID-19 Epidemic in China显示文摘In late December 2019,clinicians in Hubei Province noticed and reported to health authorities a cluster of cases of pneumonia of unknown etiology(PUE)that turned out to be the start of the coronavirus disease 2019(COVID-19)pandemic(1).By January 29,2020,all provincial-level administrative divisions(PLADs)across the country had launched their highest public health emergency responses(Level 1 responses)(2-3). | Wenzhou Yu Yuanqiu Li Jing Wu Fuzhen Wang Ning Wen Lance Rodewald Lixin Hao Yixing Li Hui Zheng Keli Li Chao Ma Dan Wu Lei Cao Lingsheng Cao Jiakai Ye Yanmin Liu Guomin Zhang Wen Du Zhijie An Huaqing Wang Zundong Yin | 2020 | China CDC weekly2020，2，34： | 1 |
| 14 | Senior Research Scholars in China CDC’s National Immunization Program显示文摘China CDC’s National Immunization Program’s Senior Research Scholars Program(NIP-SRSP)is a program created to foster the professional development of early-to-mid-career immunization experts,strengthen knowledge exchange and cooperation between national and provincial/prefectural-level CDCs,and deepen scientific and programmatic capacity of the National Immunization Program and provincial/prefectural immunization programs.Initiated in September 2019. | Miao Wang Yanmin Liu Tingting Yan Lance Rodewald Zhijie An Zundong Yin | 2021 | China CDC weekly2021，3，43： | 0 |
| 15 | “If the world doesn’t share the vaccine,the virus will take on the world”显示文摘What did George Gao mean by the title quote?The statement certainly feels like a warning,but it is a warning that comes with a prescription that carries optimism and hope.The warning that the virus will“take on the world”has indeed been the world’s experience during the first year of COVID-19.But the warning is more ominous with the continual emergence of variants of the coronavirus that have differing characteristics-transmission speed,pathogenicity,evasion of immunity to prior infection or immunization(1). | Zundong Yin Lance Rodewald Dan Wu | 2021 | China CDC weekly2021，3，13： | 0 |
| 16 | 美国免疫服务系统显示文摘预防接种是预防医学领域最成功的范例。在美国,随着疫苗的广泛使用和种类的不断增加,大多数疫苗可预防传染病正处于或接近历史最低水平。这得益于一个完善的免疫服务体系,包括基础研究、疫苗研发、疫苗生产、市场准入、免疫策略制定、免疫服务和疫苗伤害补偿系统等。但是该系统也面临巨大的挑战:包括疫苗供应、疫苗成本和安全性、成人免疫、疫苗研发和应对生物恐怖的准备。 | 张济 Lance E Rodewald | 2008 | 中国疫苗和免疫2008，14，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员